152 related articles for article (PubMed ID: 32392752)
1. On-Treatment Changes in FIB-4 and 1-Year FIB-4 Values Help Identify Patients with Chronic Hepatitis B Receiving Entecavir Therapy Who Have the Lowest Risk of Hepatocellular Carcinoma.
Wang HW; Lai HC; Hu TH; Su WP; Lu SN; Lin CH; Hung CH; Chuang PH; Wang JH; Lee MH; Chen CH; Peng CY
Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32392752
[TBL] [Abstract][Full Text] [Related]
2. Stratification of hepatocellular carcinoma risk through modified FIB-4 index in chronic hepatitis B patients on entecavir therapy.
Wang HW; Lai HC; Hu TH; Su WP; Lu SN; Lin CH; Hung CH; Chuang PH; Wang JH; Lee MH; Chen CH; Peng CY
J Gastroenterol Hepatol; 2019 Feb; 34(2):442-449. PubMed ID: 29968933
[TBL] [Abstract][Full Text] [Related]
3. One-year Fibrosis-4 index helps identify minimal HCC risk in non-cirrhotic chronic hepatitis B patients with antiviral treatment.
Tseng TC; Choi J; Nguyen MH; Peng CY; Siakavellas S; Papatheodoridis G; Wang CC; Lim YS; Lai HC; Trinh HN; Wong C; Wong C; Zhang J; Li J; Kao JH
Hepatol Int; 2021 Feb; 15(1):105-113. PubMed ID: 33547557
[TBL] [Abstract][Full Text] [Related]
4. A combination of the on-treatment FIB-4 and alpha-foetoprotein predicts clinical outcomes in cirrhotic patients receiving entecavir.
Chiang HH; Lee CM; Hu TH; Hung CH; Wang JH; Lu SN; Lai HC; Su WP; Lin CH; Peng CY; Chen CH
Liver Int; 2018 Nov; 38(11):1997-2005. PubMed ID: 29797410
[TBL] [Abstract][Full Text] [Related]
5. Impact of FIB-4 index on hepatocellular carcinoma incidence during nucleos(t)ide analogue therapy in patients with chronic hepatitis B: An analysis using time-dependent receiver operating characteristic.
Tada T; Kumada T; Toyoda H; Tsuji K; Hiraoka A; Tanaka J
J Gastroenterol Hepatol; 2017 Feb; 32(2):451-458. PubMed ID: 27288655
[TBL] [Abstract][Full Text] [Related]
6. Clinical usefulness of noninvasive fibrosis indices for predicting hepatocellular carcinoma in treatment-naïve patients with chronic hepatitis B following entecavir therapy.
Jeong J; Shin JW; Jung SW; Lee SB; Park EJ; Park NH
Hepatol Res; 2021 Sep; 51(9):923-932. PubMed ID: 34224182
[TBL] [Abstract][Full Text] [Related]
7. Prediction model of hepatocellular carcinoma in patients with hepatitis B virus-related compensated cirrhosis receiving antiviral therapy.
Wang HW; Chen CY; Lai HC; Hu TH; Su WP; Lu SN; Hung CH; Chuang PH; Wang JH; Chen CH; Peng CY
Am J Cancer Res; 2023; 13(2):526-537. PubMed ID: 36895986
[TBL] [Abstract][Full Text] [Related]
8. Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients.
Su TH; Hu TH; Chen CY; Huang YH; Chuang WL; Lin CC; Wang CC; Su WW; Chen MY; Peng CY; Chien RN; Huang YW; Wang HY; Lin CL; Yang SS; Chen TM; Mo LR; Hsu SJ; Tseng KC; Hsieh TY; Suk FM; Hu CT; Bair MJ; Liang CC; Lei YC; Tseng TC; Chen CL; Kao JH;
Liver Int; 2016 Dec; 36(12):1755-1764. PubMed ID: 27634134
[TBL] [Abstract][Full Text] [Related]
9. Changes in APRI and FIB-4 in HBeAg-negative treatment-naive chronic hepatitis B patients with significant liver histological lesions receiving 5-year entecavir therapy.
Liu R; Guo J; Lu Y; Zhang L; Shen G; Wu S; Chang M; Hu L; Hao H; Li M; Xie Y
Clin Exp Med; 2019 Aug; 19(3):309-320. PubMed ID: 31111345
[TBL] [Abstract][Full Text] [Related]
10. Relationship between virological response and FIB-4 index in chronic hepatitis B patients with entecavir therapy.
Li N; Xu JH; Yu M; Wang S; Si CW; Yu YY
World J Gastroenterol; 2015 Nov; 21(43):12421-9. PubMed ID: 26604649
[TBL] [Abstract][Full Text] [Related]
11. Fibrosis-4 Index Helps Identify HBV Carriers With the Lowest Risk of Hepatocellular Carcinoma.
Tseng TC; Liu CJ; Su TH; Yang WT; Chen CL; Yang HC; Wang CC; Kuo SF; Liu CH; Chen PJ; Chen DS; Kao JH
Am J Gastroenterol; 2017 Oct; 112(10):1564-1574. PubMed ID: 28853728
[TBL] [Abstract][Full Text] [Related]
12. Comparison of FIB-4 index and aspartate aminotransferase to platelet ratio index on carcinogenesis in chronic hepatitis B treated with entecavir.
Nishikawa H; Nishijima N; Enomoto H; Sakamoto A; Nasu A; Komekado H; Nishimura T; Kita R; Kimura T; Iijima H; Nishiguchi S; Osaki Y
J Cancer; 2017; 8(2):152-161. PubMed ID: 28243319
[TBL] [Abstract][Full Text] [Related]
13. Remaining hepatocellular carcinoma risk in chronic hepatitis B patients receiving entecavir/tenofovir in South Korea.
Yu JH; Jin YJ; Lee JW; Lee DH
Hepatol Res; 2018 Oct; 48(11):862-871. PubMed ID: 29761604
[TBL] [Abstract][Full Text] [Related]
14. HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues.
Yip TC; Wong GL; Chan HL; Tse YK; Lam KL; Lui GC; Wong VW
J Hepatol; 2019 Mar; 70(3):361-370. PubMed ID: 30367899
[TBL] [Abstract][Full Text] [Related]
15. Older Age and High α-Fetoprotein Predict Higher Risk of Hepatocellular Carcinoma in Chronic Hepatitis-B-Related Cirrhotic Patients Receiving Long-Term Nucleos(t)ide Analogue Therapy.
Liu YY; Lin CL; Weng CH; Chang PH; Chien CH; Huang KC; Hua MC; Hu CC
Diagnostics (Basel); 2022 Aug; 12(9):. PubMed ID: 36140487
[TBL] [Abstract][Full Text] [Related]
16. Additional role of liver stiffness measurement in stratifying residual hepatocellular carcinoma risk predicted by serum biomarkers in chronic hepatitis B patients under antiviral therapy.
Song BG; Sinn DH; Chi S; Kim K; Kang W; Gwak GY; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW
Eur J Gastroenterol Hepatol; 2018 Dec; 30(12):1447-1452. PubMed ID: 30063482
[TBL] [Abstract][Full Text] [Related]
17. Risk of Hepatocellular Carcinoma in Patients Treated With Entecavir vs Tenofovir for Chronic Hepatitis B: A Korean Nationwide Cohort Study.
Choi J; Kim HJ; Lee J; Cho S; Ko MJ; Lim YS
JAMA Oncol; 2019 Jan; 5(1):30-36. PubMed ID: 30267080
[TBL] [Abstract][Full Text] [Related]
18. FIB‑4 index and serum α‑fetoprotein are useful predictors of hepatocellular carcinoma occurrence in hepatitis B patients with nucleos(t)ide analogs therapy.
Kuwano A; Miyazaki M; Yada M; Tanaka K; Koga Y; Masumoto A; Motomura K
Exp Ther Med; 2023 Sep; 26(3):441. PubMed ID: 37614433
[TBL] [Abstract][Full Text] [Related]
19. The FIB-4 Index Is a Useful Predictor for the Development of Hepatocellular Carcinoma in Patients with Coexisting Nonalcoholic Fatty Liver Disease and Chronic Hepatitis B.
Kim M; Lee Y; Yoon JS; Lee M; Kye SS; Kim SW; Cho Y
Cancers (Basel); 2021 May; 13(10):. PubMed ID: 34064988
[TBL] [Abstract][Full Text] [Related]
20. Usefulness of the Fibrosis-4 index and alanine aminotransferase at 1 year of nucleos(t)ide analog treatment for prediction of hepatocellular carcinoma in chronic hepatitis B patients.
Inoue J; Akahane T; Kobayashi T; Kimura O; Sato K; Ninomiya M; Iwata T; Takai S; Kisara N; Sato T; Nagasaki F; Miura M; Nakamura T; Umetsu T; Sano A; Tsuruoka M; Onuki M; Sawahashi S; Niitsuma H; Masamune A;
Hepatol Res; 2024 Feb; 54(2):131-141. PubMed ID: 37621201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
